7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,122.70

-1,355.04

-1.73%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

Tokyo - Delayed Quote JPY

Daiichi Sankyo Company, Limited (4568.T)

2,754.00 +136.50 (+5.21%)

At close: October 30 at 3:30:00 PM GMT+9

Loading Chart for 4568.T

Chart Range Bar

Interval:

In partnership with ChartIQ

Enhertu® Wins 2026 International Prix Galien Award for Best Biotechnology Product

Enhertu® Wins 2026 International Prix Galien Award for Best Biotechnology Product

Daiichi Sankyo’s first-half profit rises on cancer drug growth; shares up

Daiichi Sankyo’s first-half profit rises on cancer drug growth; shares up

AstraZeneca holds guidance as cancer drugs outrun the Farxiga generics hit

AstraZeneca holds guidance as cancer drugs outrun the Farxiga generics hit

Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results

Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results

Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union

Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union

Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO

Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO

Will there be more to Daiichi’s story than DXd ADCs?

Will there be more to Daiichi’s story than DXd ADCs?

Daiichi Sankyo (TSE:4568) Faces Fresh Court Uncertainty After Appeal In Fortis Case

Daiichi Sankyo (TSE:4568) Faces Fresh Court Uncertainty After Appeal In Fortis Case

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

Daiichi Sankyo (TSE:4568) Stock Could Trade At A Discount As Shares Fell 28%

Daiichi Sankyo (TSE:4568) Stock Could Trade At A Discount As Shares Fell 28%

Mobilize your Website

View Site in Mobile | Classic

Share by: